R&D JPM: The calm before the storm for radiotherapeutics Radiotherapeutics have tremendous potential, but only a few therapies in market. But the technology is getting closer to its breakthrough moment.
Oncology ESMO25: Perspective on ‘inside-out oncology’ and targeted al... Perspective Therapeutics is advancing image‑guided, targeted alpha‑particle therapies (TATs). We spoke to Thijs Spoor at ESMO 2025 to find out more.
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.